10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $66,711.33 in Stock

10x Genomics, Inc. (NASDAQ:TXG) CFO Justin J. Mcanear sold 2,961 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares in the company, valued at approximately $3,227,242.26. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

10x Genomics Trading Down 1.2 %

Shares of NASDAQ TXG opened at $22.29 on Thursday. The firm’s 50-day moving average price is $19.75 and its 200-day moving average price is $28.10. 10x Genomics, Inc. has a 1-year low of $15.28 and a 1-year high of $57.90.

Analyst Ratings Changes

A number of research firms have issued reports on TXG. TD Cowen cut 10x Genomics from a “buy” rating to a “hold” rating and decreased their target price for the company from $57.00 to $32.00 in a research report on Wednesday, May 1st. Bank of America dropped their target price on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, July 18th. Canaccord Genuity Group dropped their price target on shares of 10x Genomics from $50.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, July 23rd. Stifel Nicolaus reduced their price objective on shares of 10x Genomics from $53.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, July 16th. Finally, The Goldman Sachs Group lowered their target price on 10x Genomics from $26.00 to $16.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $31.46.

Institutional Trading of 10x Genomics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its position in 10x Genomics by 48.2% in the 2nd quarter. ARK Investment Management LLC now owns 9,313,763 shares of the company’s stock valued at $181,153,000 after purchasing an additional 3,029,951 shares during the period. Vanguard Group Inc. grew its holdings in shares of 10x Genomics by 1.0% during the first quarter. Vanguard Group Inc. now owns 9,101,536 shares of the company’s stock valued at $341,581,000 after buying an additional 90,204 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of 10x Genomics by 69.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock valued at $119,483,000 after buying an additional 2,521,289 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of 10x Genomics by 17.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,657,227 shares of the company’s stock worth $137,257,000 after acquiring an additional 553,053 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. raised its holdings in shares of 10x Genomics by 58.6% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 3,621,778 shares of the company’s stock worth $135,780,000 after acquiring an additional 1,338,248 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.